-
EP4028056
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4028056
| EP4028056 - METHODS OF TREATING CANCER BY THE USE OF PD-1 AXIS INHIBITORS AND ANTI-PERIOSTIN ANTIBODIES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 20.06.2024 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 17.06.2022 | ||
| Former | The international publication has been made Status updated on 20.03.2021 | Most recent event Tooltip | 20.06.2024 | Application deemed to be withdrawn | published on 24.07.2024 [2024/30] | Applicant(s) | For all designated states Boehringer Ingelheim IO Canada Inc. 5180 South Service Road Burlington Ontario L7L 5H4 / CA | [2022/29] | Inventor(s) | 01 /
JETHA, Arif c/o VP, IP, Legal Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, Connecticut 06877-0368 / US | 02 /
FRANSSON, Johan C/o VP, IP, Legal Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, Connecticut 06877-0368 / US | 03 /
MCGRAY, AJ Robert c/o VP, IP, Legal Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, Connecticut 06877-0368 / US | 04 /
HULME, Joanne C/o VP, IP, Legal Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, Connecticut 06877-0368 / US | [2022/29] | Representative(s) | Lutze, Oliver, et al Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein / DE | [N/P] |
| Former [2022/29] | Simon, Elke Anna Maria, et al Boehringer Ingelheim International GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | Application number, filing date | 20862817.2 | 27.08.2020 | [2022/29] | WO2020CA51164 | Priority number, date | US201962899066P | 11.09.2019 Original published format: US 201962899066 P | [2022/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021046634 | Date: | 18.03.2021 | Language: | EN | [2021/11] | Type: | A1 Application with search report | No.: | EP4028056 | Date: | 20.07.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.03.2021 takes the place of the publication of the European patent application. | [2022/29] | Search report(s) | International search report - published on: | CA | 18.03.2021 | (Supplementary) European search report - dispatched on: | EP | 12.09.2023 | Classification | IPC: | A61K39/395, A61P35/00, C07K16/18, C07K16/28 | [2022/29] | CPC: |
C07K16/2818 (EP,KR,US);
C07K16/18 (EP,KR,US);
A61K45/06 (KR);
A61P1/00 (US);
A61P13/10 (US);
A61P35/00 (EP,KR,US);
A61K2039/505 (EP,KR);
A61K2039/507 (EP,KR,US);
A61K2039/545 (US);
C07K2317/24 (US);
C07K2317/56 (EP);
C07K2317/565 (EP,US);
C07K2317/622 (EP,KR);
C07K2317/76 (EP);
C07K2317/92 (EP,KR,US);
C07K2319/30 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/29] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON KREBS DURCH VERWENDUNG VON PD-1-AXIS-INHIBITOREN UND ANTI-PERIOSTIN-ANTIKÖRPERN | [2022/29] | English: | METHODS OF TREATING CANCER BY THE USE OF PD-1 AXIS INHIBITORS AND ANTI-PERIOSTIN ANTIBODIES | [2022/29] | French: | MÉTHODES DE TRAITEMENT DU CANCER PAR L'UTILISATION D'INHIBITEURS DE L'AXE PD-1 ET D'ANTICORPS ANTI-PÉRIOSTINE | [2022/29] | Entry into regional phase | 11.04.2022 | National basic fee paid | 11.04.2022 | Search fee paid | 11.04.2022 | Designation fee(s) paid | 11.04.2022 | Examination fee paid | Examination procedure | 11.04.2022 | Examination requested [2022/29] | 21.10.2022 | Amendment by applicant (claims and/or description) | 01.03.2024 | Application deemed to be withdrawn, date of legal effect [2024/30] | 27.03.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2024/30] | Fees paid | Renewal fee | 31.08.2022 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.08.2023 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XP]WO2020121059 (NORTHERN BIOLOGICS INC [CA]) [XP] 1-15* Anti-periostin antibody heavy chain variable region and light chan, SEQ 13.;; examples 1-7; claims 1-66 *; | [I] - TAKU FUJIMURA ET AL, "Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study", ONCOTARGET, (20180320), vol. 9, no. 21, doi:10.18632/oncotarget.24509, pages 15542 - 15551, XP055708289 [I] 1-15 * page 15543, column 2, paragraph last; figure 2 * * page 15547, column 1 * DOI: http://dx.doi.org/10.18632/oncotarget.24509 | [A] - PAOLA ORECCHIA ET AL, "Identification of a novel cell binding site of periostin involved in tumour growth", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, vol. 47, no. 14, doi:10.1016/J.EJCA.2011.04.026, ISSN 0959-8049, (20110419), pages 2221 - 2229, (20110426), XP028286215 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.ejca.2011.04.026 | [A] - SARAH FIELD ET AL, "Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, (20151221), vol. 138, no. 8, doi:10.1002/IJC.29946, ISSN 0020-7136, pages 1959 - 1970, XP071288727 [A] 1-15 * abstract * DOI: http://dx.doi.org/10.1002/ijc.29946 | [A] - RYUICHI MORISHITA, "Role of periostin in cancer progression and metastasis: Inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, (20110101), vol. 28, doi:10.3892/ijmm.2011.712, ISSN 1107-3756, pages 181 - 186, XP055184380 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.3892/ijmm.2011.712 | International search | [Y]WO2019063802 (BOEHRINGER INGELHEIM INT [DE]) [Y] 1, 2, 8, 9, 14-22, 27-31, 33-35, 41-49, 52 and 53 * The whole document *; | [Y] - Nakazawa Youya, Taniyama Yoshiaki, Sanada Fumihiro, Morishita Ryuichi, Nakamori Shoji, Morimoto Koji, Yeung Kay T., Yang Jing, "Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cance r", SCIENTIFIC REPORTS, (20180305), vol. 8, no. 1, ISSN 2045-2322, page 4013, XP055803217 [Y] 1, 2, 8, 9, 14-22, 27-31, 33-35,41-49, 52 and 53 * The whole document * DOI: http://dx.doi.org/10.1038/s41598-018-22340-7 | [Y] - GUZIK et al., "Development of the inhibitors that target the PD-1/PD-L1 interaction - A brief look at progress on small molecules, peptides and macrocycles", MOLECULES, (20190530), vol. 24, no. 11, ISSN 1420-3049, page 2071, XP055615035 [Y] 1, 23, 24, 50 and 51 * The whole document * DOI: http://dx.doi.org/10.3390/molecules24112071 | [Y] - MEYERS et al., "Targeting the PD-1/PD-L1 axis for the treatment of non-small- cell lung cancer", CURRENT ONCOLOGY, (20180800), vol. 25, no. 4, ISSN 1198-0052, pages e324 - e334, XP055803218 [Y] 1, 25 and 26 * The whole document * DOI: http://dx.doi.org/10.3747/co.25.3976 |